Den europeiske union - norsk - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressive - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Norge - norsk - Statens legemiddelverk

glenmark arzneimittel gmbh - dimetylfumarat - enterokapsel, hard - 240 mg

Norge - norsk - Statens legemiddelverk

glenmark arzneimittel gmbh - dimetylfumarat - enterokapsel, hard - 120 mg